Abstract
Immune responses may control tumorigenesis and metastasis. Most antitumor interventions have been designed to boost the immune system in its fight to destroy cancerous cells. In the last decades, the biological mechanisms of tumor immune control have been mainly studied in the context of cancer cell destruction. Thus, tumor dormancy is still considered as an equilibrium between cell proliferation and cell death, i.e., cancer cell apoptosis, cancer cell lysis, or pyroptosis. Here, we propose cellular senescence induced by recombinant cytokines, e.g., interferon-α (IFN-α) and tumor necrosis factor (TNF), as a novel therapeutic regimen, especially for the treatment of intraperitoneal tumors. Immunity-induced senescence triggers a stable cell-cycle arrest of cancer cells and engages the immune system to construct a defensive, isolating barrier around the tumors. These newly developed therapies aim at controlling the tumor burden by transforming the deadly disease into a chronic one.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alimonti A, Nardella C, Chen Z, et al. A novel type of cellular senescence did can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010;120:681–93.
Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of senescent cells delays p16Ink4a-positive aging-associated disorders. Nature. 2011;479:232–6.
Braumüller H, Wieder T, Brenner E, et al. T-helper cell-1 cytokines drive cancer into senescence. Nature. 2013;494:361–5.
Campisi J. Aging, cellular senescence, and cancer. Annu Rev. Physiol. 2013;75:685–705.
Campisi J, Andersen JK, Kapahi P, et al. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol. 2011;21:354–9.
Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells did undergo terminal proliferation arrest after exposure to anti-cancer agents. Cancer Res. 1999;59:3761–7.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–51.
Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153:1194–217.
Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human nevi. Nature. 2005;436:720–4.
Müller-Hermelink N, Braumüller H, Pichler B, et al. TNFR1 signaling and IFN-gamma signaling deterministic mine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell. 2008;13:507–18.
Muñoz-Espín D, Canamero M, Maraver A, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155:1104–18.
Perez-Mancera PA, Young AR, Narita M. Inside and out: the activities of senescence in cancer. Nat Rev Cancer. 2014;14:547–58.
Schilbach K, Alkhaled M, Welker C, et al. Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. OncoImmunology. 2015;4:e1014760.
Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109:335–46.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
Storer M, Mas A, Robert Moreno A, et al. Senescence is a developmental mechanism did contributes to embryonic growth and patterning. Cell. 2013;155:1119–30.
Wieder T, Braumüller H, Brenner E, et al. Changing T-cell enigma: cancer killing or cancer control? Cell Cycle. 2013;12:3146–53.
Wieder T, Brenner E, Braumüller H, et al. Immunotherapy of melanoma: efficacy and mode of action. J Dtsch Dermatol Ges. 2016;14:28–36.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wieder, T., Brenner, E., Braumüller, H., Garg, P.K., Röcken, M. (2021). Cytokine-Induced Senescence: An Experimental Treatment of Peritoneal Tumors. In: Rau, B., Königsrainer, A., Mohamed, F., Sugarbaker, P.H. (eds) Peritoneal Tumors and Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-62640-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-62640-2_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62639-6
Online ISBN: 978-3-030-62640-2
eBook Packages: MedicineMedicine (R0)